R&D channel feed – Endpoints News

R&D channel feed

Resistant to CAR-T therapies? It's the cancer, not your immune system — study

6 years ago

With deals in tow, Roche ends 2019 with five discarded programs

6 years ago

Eli Lilly notches another positive baricitinib eczema trial, but has Dermira made it obsolete?

6 years ago

Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out

6 years ago

Rani Therapeutics eyes potential IPO as robotic pill technology takes shape

6 years ago

Sanofi polishes rare disease profile as Niemann-Pick drug scores promising PhII/III data — there's just one question

6 years ago

The first drug from Eli Lilly's new-look oncology group gets speedy review as Bilenker's team hones focus

6 years ago

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year

6 years ago

What in the world is a MINOR CRL, Amphastar?

6 years ago

Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus. To STING

6 years ago

Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve been alerted

6 years ago

Ionis/Akcea's Pfizer-partnered antisense drug shows promise in study, with implications for Arrowhead RNAi asset — analysts

6 years ago

Pfizer axes 6 early to late-stage cancer studies from the pipeline — with one other cut for sickle cell disease

6 years ago

Incyte scores much needed PhIII success — and of course it’s delivered by ruxolitinib

6 years ago

Can we make the antibiotic market great again?

6 years ago

Ex-Novartis CEO Joe Jimenez is taking another crack at opening a new chapter in his career — and that includes a new board seat and a $250M startup

6 years ago

Acceleron resurrects blockbuster hopes for sotatercept with positive PhII — and shares rocket up

6 years ago

Civica and Blue Cross Blue Shield launch new venture to lower generic prices

6 years ago

Merck KGaA matches lofty R&D goals with €250M investment into a new clinical manufacturing site in Switzerland

6 years ago

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

6 years ago

Short attacker Sahm Adrangi draws crosshairs over a favorite of Sanofi’s new CEO — with PhII data looming

6 years ago

Sorrento shrugs off an anonymous private equity group’s $1B offer to buy the company

6 years ago

AstraZeneca makes case for use of blood thinner Brilinta in stroke patients

6 years ago

A $1B-plus drug stumbles into another big PhIII setback — this time flunking futility test — as FDA hold remains in effect for Ipsen

6 years ago

First page Previous page 213 214 215216217 218 219 Next page Last page